Nebenwirkungen · Talmanco (previously Tadalafil Generics)
Talmanco 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 10
HOS-137568 · Präparat HOS-098059
Post-marketing study in paediatric patients (H6D-JE-TD01) Safety data were collected during an observational post-marketing study in Japan including 391 paediatric PAH patients (2 years maximum observational period). The mean age of patients in the study was 5.7 ± 5.3 years, including 79 patients aged < 1 year, 41 aged 1 to < 2 years, 122 aged 2 to 6 years, 110 aged 7 to 14 years, and 39 aged 15 to 17 years. AEs were reported in 123 patients (31.5 %). The incidences of AEs (≥ 5 patients) were pulmonary hypertension (3.6 %); headache
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T02:00:00Z · SHA-256 9416206846678eeb980d8118e3703862499194c0ef267c815ee4a68563143115 · Passage e06cce8a78bceaf230f09df75da8092b2f650fb5e6805d04b9ea74974781a1f5 · Zeichen 9215–9753 im Abschnitt